Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements

Trial Profile

A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Nivolumab (Primary) ; Prednisolone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms HO152; HOVON 152 DLBCL
  • Most Recent Events

    • 10 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top